Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Theravance Biopharma excels in Q2 with strong sales growth

Theravance Biopharma delivered strong financial performance in Q2 2024, driven by robust sales of YUPELRI and Trelegy.
While facing challenges such as ongoing losses and R&D expenses, the company remains focused on innovation and operational efficiency.
With a solid cash position, key patent grants, and growth opportunities in new markets, Theravance is poised for future growth and value creation.
Investors can look forward to potential milestones and market expansion initiatives as Theravance continues to execute its strategic vision.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

Theravance Bio (TBPH) Up 25.6% Since Last Earnings Report: Can It Continue?

AbbVie

Biogen

Innoviva

Mylan

Novartis

Regeneron Pharmaceuticals

With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.

7 Biotech Stocks to Buy With Plenty of Power in the Pipeline        

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q3 2019 - Earnings Call Transcript

Theravance's (TBPH) third-quarter loss matches estimates while revenues miss the same in absence of product sales due to the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.

Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 0.00% and -6.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Reports Q3 Loss, Misses Revenue Estimates

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Neil Woodford, the unlucky British fund manager who was yesterday ousted from his flagship fund, is (was) Theravance's largest shareholder.

Theravance: The Worst Might Be Over

Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.

Theravance Announces Positive Early Data on JAK Inhibitor

Theravance Biopharma has had a 'stealth' 20% rally over the last month despite the recent spike in market volatility.

Theravance Biopharma: Gaining Traction

Theravance (TBPH) reports narrower-than-expected loss and beats on sales in the second quarter of 2019.

Theravance (TBPH) Q2 Loss Narrower, Revenues Beat Estimates

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q2 2019 Results - Earnings Call Transcript

Theravance Bio (TBPH) delivered earnings and revenue surprises of 40.98% and 87.91%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates

Theravance Bio (TBPH) Down 27.7% Since Last Earnings Report: Can It Rebound?

Theravance Biopharma (TBPH) retains its earlier issued guidance for 2019 operating loss sans non-cash share-based compensation in the range of $210-$230 million.

Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q1 2019 Results - Earnings Call Transcript

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Theravance Bio (TBPH) Down 7.9% Since Last Earnings Report?

News for Theravance Biopharma Stock (TBPH)